{"entity":{"id":"neu-001","kind":"drug","name":"N17350","aka":["NEU-001"],"tldr":"N17350 is an experimental enzyme therapy: elastase injected into the tumour from Onchilles Pharma, in phase 1 trials for advanced solid tumours, triple-negative breast cancer and cutaneous squamous cell carcinoma and other cancers.","summary":"N17350 (NEU-001) is an enzyme therapy: elastase injected into the tumour from Onchilles Pharma. A tumour-directed therapeutic elastase designed to kill cancer cells selectively while preserving immune cells, causing immunogenic cancer cell death that stimulates anti-tumour immunity; the company says it works through the ELANE pathway, which targets altered histone H1 biology. Its furthest stage is phase 1, for advanced solid tumours, triple-negative breast cancer, cutaneous squamous cell carcinoma and melanoma. ClinicalTrials.gov registers it in one study linked below. OP-NEU-101 phase 1/2 (NCT07339176, registry PHASE1/PHASE2, recruiting) enrolling in the US and Australia; first patient dosed announced 4 June 2026. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Onchilles Pharma: onchillespharma.com","url":"https://www.onchillespharma.com/"},{"label":"Onchilles Pharma: onchillespharma.com","url":"https://www.onchillespharma.com/"},{"label":"Onchilles Pharma: onchillespharma.com","url":"https://www.onchillespharma.com/"},{"label":"Onchilles Pharma: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07339176"},{"label":"ClinicalTrials.gov: trials of NEU-001","url":"https://clinicaltrials.gov/search?intr=NEU-001"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","cutaneous-scc","melanoma","head-and-neck","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["onchilles-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07339176"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"NEU-001","modality":"Enzyme therapy: elastase injected into the tumour","mechanism":"A tumour-directed therapeutic elastase designed to kill cancer cells selectively while preserving immune cells, causing immunogenic cancer cell death that stimulates anti-tumour immunity; the company says it works through the ELANE pathway, which targets altered histone H1 biology.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/neu-001/","neighbours":{"cancer":[{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"onchilles-pharma","kind":"company","name":"Onchilles Pharma","route":"/companies/onchilles-pharma/"}],"trial":[{"id":"nct07339176","kind":"trial","name":"Intratumoral N17350 in Advanced Solid Tumors","route":"/trials/nct07339176/"}]}}